Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.43 |
| ▸ | F2R | P25116 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29891111 | 0.98 | GABRA5 (0.45) | GABRA5GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL6618139 | 0.88 | LMNA (0.43) | GABRA5GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL17338045 | 0.86 | LMNA (0.42) | GABRA5GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL8078390 | 0.84 | — | — | |
| SCHEMBL9320849 | 0.79 | PTGS1 (0.36) | LMNAITGB3ITGA2BF2R | |
| SCHEMBL4072061 | 0.79 | ALDH1A1 (0.37) | LMNA | |
| SCHEMBL230908 | 0.78 | CHRM1 (0.38) | GABRA5GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL310513 | 0.78 | CHRM1 (0.38) | GABRA5GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL10696697 | 0.78 | GABRA5 (0.42) | GABRA5GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL10512591 | 0.77 | GABRA5 (0.50) | GABRA5GABRA1TSHRGABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4726304-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| JP-2003517458-A | — | — | 2003-05-27 | — | — | JP | claimed |
| EP-1276483-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-01-22 | — | — | EP | claimed |
| WO-2000064420-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-11-02 | — | — | WO | claimed |
| EP-4593959-A1 | SOLUBILIZING COMPOUNDS | Vivesto AB (SE) | 2025-08-06 | — | — | EP | disclosed |
| CN-119998262-A | Solubilizing compounds | 维维斯多公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240391948-A1 | NOVEL COMPOUND THAT INHIBITS TNF-ALPHA GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR | SHAPERON INC. (KR) | 2024-11-28 | — | — | US | disclosed |
| EP-4378946-A1 | NOVEL COMPOUND THAT INHIBITS TNF-A GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR | Shaperon Inc. (KR) | 2024-06-05 | — | — | EP | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024068553-A1 | SOLUBILIZING COMPOUNDS | VIVESTO AB (SE) | 2024-04-04 | — | — | WO | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
| EP-1988078-B1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | ORTHO MCNEIL PHARM INC (US) | 2012-10-17 | — | — | EP | disclosed |
| CN-1286684-A | Carboxamide derivs. of pyrrolidine, piperidine and hexahydroazepine for treatment of thrombosis disorders | ORTHO PHARMA CORP (US) | 2001-03-07 | — | — | CN | disclosed |
| EP-0923555-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997041102-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-11-06 | — | — | WO | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391948-A1 | NOVEL COMPOUND THAT INHIBITS TNF-ALPHA GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR | TNF, IL1B, IL1A | GABRA5 1963/4885GABRA1 1468/4885TSHR 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.